AR003455A1 - Derivados tetraciclicos, su uso en la preparacion de un medicamento, un metodo de tratamiento, una composicion farmaceutica y procesos para lapreparacion de una composicion farmaceutica y para preparar los compuestos. - Google Patents
Derivados tetraciclicos, su uso en la preparacion de un medicamento, un metodo de tratamiento, una composicion farmaceutica y procesos para lapreparacion de una composicion farmaceutica y para preparar los compuestos.Info
- Publication number
- AR003455A1 AR003455A1 ARP960103558A AR10355896A AR003455A1 AR 003455 A1 AR003455 A1 AR 003455A1 AR P960103558 A ARP960103558 A AR P960103558A AR 10355896 A AR10355896 A AR 10355896A AR 003455 A1 AR003455 A1 AR 003455A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- pharmaceutical composition
- derivatives
- tetraciclic
- prepare
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen derivados tetracíclicos de la fórmula (I) y los solvatos del mismo, en la cual: R(0) representa hidrógeno, halógeno o alquilo de 1 a 6átomos de carbono;R1 representa hidrógeno o alquilo de 1 a 6 átomos de carbono; R2 representa unanil lo bicíclico,el cual puede estar sustituido por uno o másgrupos seleccionados de halógeno y alquilo de 1 a 3 átomos de carbono; y R3 representa hidrógeno o alquilo de 1 a 3 átomos de carbono. Son inhibidorespotentes y selectivos de lafosfodieste rasa específica del 3, 5-monofosfato de guanosina cíclica (PED específico de cGMP)que tiene utilidad en una variedadde áreas terapéuticas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9514465.5A GB9514465D0 (en) | 1995-07-14 | 1995-07-14 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR003455A1 true AR003455A1 (es) | 1998-08-05 |
Family
ID=10777696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP960103558A AR003455A1 (es) | 1995-07-14 | 1996-07-12 | Derivados tetraciclicos, su uso en la preparacion de un medicamento, un metodo de tratamiento, una composicion farmaceutica y procesos para lapreparacion de una composicion farmaceutica y para preparar los compuestos. |
Country Status (24)
Country | Link |
---|---|
US (1) | US5981527A (es) |
EP (1) | EP0846118B1 (es) |
JP (1) | JP4150818B2 (es) |
CN (1) | CN1069318C (es) |
AR (1) | AR003455A1 (es) |
AT (1) | ATE216997T1 (es) |
AU (1) | AU702324B2 (es) |
BR (1) | BR9609780A (es) |
CA (1) | CA2226761A1 (es) |
CO (1) | CO4700455A1 (es) |
CZ (1) | CZ3298A3 (es) |
DE (1) | DE69621026T2 (es) |
ES (1) | ES2176471T3 (es) |
GB (1) | GB9514465D0 (es) |
HR (1) | HRP960321B1 (es) |
HU (1) | HUP9900006A3 (es) |
IL (1) | IL122923A0 (es) |
MX (1) | MX9800411A (es) |
NO (1) | NO980154L (es) |
PL (1) | PL324527A1 (es) |
SK (1) | SK3898A3 (es) |
WO (1) | WO1997003985A1 (es) |
YU (1) | YU42296A (es) |
ZA (1) | ZA965934B (es) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
US6262059B1 (en) | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
US5874440A (en) * | 1995-06-07 | 1999-02-23 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives |
US6232312B1 (en) | 1995-06-07 | 2001-05-15 | Cell Pathways, Inc. | Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides |
US6060477A (en) * | 1995-06-07 | 2000-05-09 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives |
US6200980B1 (en) | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
GB9514473D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
DE69833254T2 (de) | 1997-06-23 | 2006-11-02 | Cellegy Pharmaceuticals, Inc., Brisbane | Microdosistherapie von gefässbedingten erscheinungen durch no-donoren |
ES2137113B1 (es) | 1997-07-29 | 2000-09-16 | Almirall Prodesfarma Sa | Nuevos derivados de triazolo-piridazinas heterociclicos. |
US5852035A (en) * | 1997-12-12 | 1998-12-22 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines |
US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
US6046199A (en) * | 1998-01-14 | 2000-04-04 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives |
US5942520A (en) * | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
US5990117A (en) * | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
US6268372B1 (en) | 1998-09-11 | 2001-07-31 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones |
US6124303A (en) * | 1998-09-11 | 2000-09-26 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones |
US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
JP2002543128A (ja) * | 1999-04-30 | 2002-12-17 | リリー アイコス リミテッド ライアビリティ カンパニー | 雌性覚醒障害の処置 |
US6451807B1 (en) | 1999-04-30 | 2002-09-17 | Lilly Icos, Llc. | Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor |
NO20002097L (no) * | 1999-04-30 | 2001-10-26 | Lilly Icos Llc | Fremstillingsgjenstander |
EP1200090B1 (en) * | 1999-08-03 | 2013-09-11 | ICOS Corporation | Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction |
US20040152106A1 (en) * | 1999-10-07 | 2004-08-05 | Robertson Harold A. | Gene necessary for striatal function, uses thereof, and compounds for modulating same |
WO2001024781A2 (en) * | 1999-10-07 | 2001-04-12 | Novaneuron Inc. | Gene necessary for striatal function, uses thereof, and compounds for modulating same |
NZ517324A (en) | 1999-10-11 | 2003-09-26 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-YL)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
IL139457A0 (en) | 1999-11-08 | 2001-11-25 | Pfizer | Compounds for the treatment of female sexual dysfunction |
US20050070499A1 (en) * | 1999-11-08 | 2005-03-31 | Pfizer Inc. | Compounds for the treatment of female sexual dysfunction |
US6569638B1 (en) | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
DE60124085D1 (de) | 2000-04-19 | 2006-12-07 | Lilly Icos Llc | Pde-v hemmer zur behandlung von morbus parkinson |
CN1630532A (zh) * | 2000-04-19 | 2005-06-22 | 约翰斯霍普金斯大学 | 预防和治疗胃肠疾病的方法 |
WO2002000658A1 (en) * | 2000-06-23 | 2002-01-03 | Lilly Icos Llc | Cyclic gmp-specific phosphodiesterase inhibitors |
WO2002010166A1 (en) * | 2000-08-02 | 2002-02-07 | Lilly Icos Llc | Fused heterocyclic derivatives as phosphodiesterase inhibitors |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
KR100610131B1 (ko) * | 2000-09-06 | 2006-08-09 | 다나베 세이야꾸 가부시키가이샤 | 경구 투여용 제제 |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
AU2002213419A1 (en) | 2000-10-02 | 2002-04-15 | Lilly Icos Llc | Condensed pyridoindole derivatives |
ATE297926T1 (de) * | 2000-10-02 | 2005-07-15 | Lilly Icos Llc | Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen |
CA2427573C (en) | 2000-11-06 | 2008-10-07 | Lilly Icos Llc | Indole derivatives as pde5-inhibitors |
US6960587B2 (en) | 2000-11-08 | 2005-11-01 | Lilly Icos Llc | Condensed pyrazindione derivatives as PDE inhibitors |
US7927623B2 (en) * | 2001-02-15 | 2011-04-19 | Mitsubishi Tanabe Pharma Corporation | Tablets quickly disintegrated in oral cavity |
DE10118306A1 (de) | 2001-04-12 | 2002-10-17 | Bayer Ag | Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation |
DE10118305A1 (de) * | 2001-04-12 | 2002-10-17 | Bayer Ag | Zusammensetzungen zur nasalen Applikation |
CA2445620C (en) * | 2001-06-05 | 2008-07-08 | Lilly Icos Llc | Tetracyclic compounds as pde5-inhibitors |
DE60213798T2 (de) | 2001-06-21 | 2007-08-16 | Lilly Icos Llc, Wilmington | Carbolinderivate als pdev inhibitoren |
CA2465893A1 (en) * | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
CA2469075C (en) | 2001-12-20 | 2011-09-13 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
CA2492540C (en) * | 2002-07-31 | 2010-05-04 | Lilly Icos, Llc | Modified pictet-spengler reaction and products prepared therefrom |
PT1644021E (pt) * | 2003-06-13 | 2013-01-30 | Ironwood Pharmaceuticals Inc | Métodos e composições para o tratamento de distúrbios gastrointestinais |
WO2006049986A1 (en) * | 2004-10-28 | 2006-05-11 | Dr. Reddy's Laboratories Ltd. | Polymorphic forms of tadalafil |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
EP1956906A4 (en) | 2005-11-09 | 2009-12-30 | Combinatorx Inc | METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
MX2009002496A (es) * | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
EP2903619B1 (en) | 2012-10-05 | 2019-06-05 | Robert I. Henkin | Phosphodiesterase inhibitors for treating taste and smell disorders |
CN104230960B (zh) * | 2013-06-06 | 2017-02-15 | 山东轩竹医药科技有限公司 | 四并环类间变性淋巴瘤激酶抑制剂 |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
CN104804016B (zh) * | 2014-01-23 | 2017-06-20 | 山东轩竹医药科技有限公司 | 四并环类间变性淋巴瘤激酶抑制剂 |
US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
ES2749433T3 (es) | 2014-06-23 | 2020-03-20 | Celgene Corp | Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática |
EP3728266A1 (en) | 2017-12-20 | 2020-10-28 | Novartis AG | Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals |
BR112020017561A2 (pt) | 2018-02-28 | 2020-12-22 | Ferro Therapeutics, Inc. | Compostos com atividade indutora de ferroptose e métodos de seu uso |
US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3644384A (en) * | 1969-06-09 | 1972-02-22 | Sterling Drug Inc | Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives |
US3717638A (en) * | 1971-03-11 | 1973-02-20 | Sterling Drug Inc | 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR |
US3917599A (en) * | 1973-03-30 | 1975-11-04 | Council Scient Ind Res | 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles |
GB1454171A (en) * | 1973-10-19 | 1976-10-27 | Council Scient Ind Res | Tetracyclic compounds |
US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
GR79603B (es) * | 1982-07-24 | 1984-10-31 | Pfizer | |
IT1217190B (it) * | 1988-04-22 | 1990-03-14 | Recordati Chem Pharm | Composti utili per il trattamento e diagnosi di disfunzioni frettili |
EP0357122A3 (en) * | 1988-08-29 | 1991-10-23 | Duphar International Research B.V | Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties |
DE3830096A1 (de) * | 1988-09-03 | 1990-03-15 | Hoechst Ag | Piperazindione mit psychotroper wirkung |
FR2649613B1 (fr) * | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
JPH0344324A (ja) * | 1989-07-13 | 1991-02-26 | Kazuoki Tsuchiya | 性機能賦活剤 |
US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
DK0459666T3 (da) * | 1990-05-31 | 1994-12-05 | Pfizer | Lægemidler mod impotens |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9218322D0 (en) * | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
-
1995
- 1995-07-14 GB GBGB9514465.5A patent/GB9514465D0/en active Pending
-
1996
- 1996-07-05 HR HR960321A patent/HRP960321B1/xx not_active IP Right Cessation
- 1996-07-11 AU AU64192/96A patent/AU702324B2/en not_active Ceased
- 1996-07-11 IL IL12292396A patent/IL122923A0/xx unknown
- 1996-07-11 BR BR9609780A patent/BR9609780A/pt not_active Application Discontinuation
- 1996-07-11 CN CN96196751A patent/CN1069318C/zh not_active Expired - Fee Related
- 1996-07-11 PL PL96324527A patent/PL324527A1/xx unknown
- 1996-07-11 WO PCT/EP1996/003025 patent/WO1997003985A1/en active IP Right Grant
- 1996-07-11 AT AT96923986T patent/ATE216997T1/de active
- 1996-07-11 US US09/000,192 patent/US5981527A/en not_active Expired - Lifetime
- 1996-07-11 DE DE69621026T patent/DE69621026T2/de not_active Expired - Fee Related
- 1996-07-11 CZ CZ9832A patent/CZ3298A3/cs unknown
- 1996-07-11 SK SK38-98A patent/SK3898A3/sk unknown
- 1996-07-11 JP JP50624997A patent/JP4150818B2/ja not_active Expired - Fee Related
- 1996-07-11 ES ES96923986T patent/ES2176471T3/es not_active Expired - Lifetime
- 1996-07-11 CA CA002226761A patent/CA2226761A1/en not_active Abandoned
- 1996-07-11 HU HU9900006A patent/HUP9900006A3/hu unknown
- 1996-07-11 EP EP96923986A patent/EP0846118B1/en not_active Expired - Lifetime
- 1996-07-11 MX MX9800411A patent/MX9800411A/es not_active Application Discontinuation
- 1996-07-12 YU YU42296A patent/YU42296A/sh unknown
- 1996-07-12 CO CO96036775A patent/CO4700455A1/es unknown
- 1996-07-12 AR ARP960103558A patent/AR003455A1/es unknown
- 1996-07-12 ZA ZA9605934A patent/ZA965934B/xx unknown
-
1998
- 1998-01-13 NO NO980154A patent/NO980154L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DE69621026D1 (de) | 2002-06-06 |
JPH11509535A (ja) | 1999-08-24 |
SK3898A3 (en) | 1998-11-04 |
MX9800411A (es) | 1998-04-30 |
NO980154D0 (no) | 1998-01-13 |
HRP960321B1 (en) | 2003-06-30 |
JP4150818B2 (ja) | 2008-09-17 |
HUP9900006A3 (en) | 1999-11-29 |
AU702324B2 (en) | 1999-02-18 |
HRP960321A2 (en) | 1998-08-31 |
PL324527A1 (en) | 1998-06-08 |
US5981527A (en) | 1999-11-09 |
CN1069318C (zh) | 2001-08-08 |
BR9609780A (pt) | 1999-03-09 |
WO1997003985A1 (en) | 1997-02-06 |
HUP9900006A2 (hu) | 1999-04-28 |
IL122923A0 (en) | 1998-08-16 |
ATE216997T1 (de) | 2002-05-15 |
CA2226761A1 (en) | 1997-02-06 |
EP0846118A1 (en) | 1998-06-10 |
GB9514465D0 (en) | 1995-09-13 |
DE69621026T2 (de) | 2002-08-22 |
EP0846118B1 (en) | 2002-05-02 |
CZ3298A3 (cs) | 1998-06-17 |
YU42296A (sh) | 1998-12-23 |
ZA965934B (en) | 1997-02-03 |
ES2176471T3 (es) | 2002-12-01 |
AU6419296A (en) | 1997-02-18 |
CO4700455A1 (es) | 1998-12-29 |
CN1195349A (zh) | 1998-10-07 |
NO980154L (no) | 1998-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR003455A1 (es) | Derivados tetraciclicos, su uso en la preparacion de un medicamento, un metodo de tratamiento, una composicion farmaceutica y procesos para lapreparacion de una composicion farmaceutica y para preparar los compuestos. | |
DK0641342T3 (da) | Antivirale 2-ethyl-1H-imidazo(4,5-c)quinolin-4-aminer | |
AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
SV1995000002A (es) | Uso y obtencion de derivados tetraciclicos ref. 1233cv/vs | |
ES2094141T3 (es) | 1h-imidazo(4,5-c)quinolin-4-aminas como antivirales. | |
ES2011210T3 (es) | Derivados de gem-difosfonato substituido, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
ES2060026T3 (es) | 1h-imidazo(4,5-c)quinolin-4-aminas olefinicas. | |
AR024242A1 (es) | COMPUESTO HETEROBICICLO CON CONTENIDO DE NITROGENO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE , Y EL USO DE DICHOS COMPUESTOS EN LA FABRICACIoN DE UN MEDICAMENTO. | |
AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
UY24560A1 (es) | Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos | |
AR045134A1 (es) | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic | |
ECSP055609A (es) | "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor" | |
ES2186677T3 (es) | Derivados de deuteroporfirina sustituidos en las posiciones 3 y 8, agentes farmaceuticos que contienen estos derivados y procedimientos para su preparacion. | |
PA8432901A1 (es) | Compuestos de piridilpirrol | |
AR002012A1 (es) | Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto. | |
MX9307011A (es) | Derivados hidrosolubles de camptotecina, proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
MX9300407A (es) | Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion. | |
ES2052603T3 (es) | Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen. | |
MX9401080A (es) | Compuestos heteroaromaticos. | |
AR005102A1 (es) | Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento. | |
AR044275A1 (es) | Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias | |
ES2127263T3 (es) | Nuevos trien-derivados cromenicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
ES2157899T3 (es) | Derivados de sampangina utiles como agentes antifungicos y antimicobacterianos. | |
DK0631474T3 (da) | Cykliske antitumor-promotorforbindelser, sammensætninger og fremgangsmåde til fremstilling såvel som anvendelse heraf |